Bridging the age gap in breast cancer: impact of omission of breast cancer surgery in older women with oestrogen receptor-positive early breast cancer on quality-of-life outcomes by Morgan, J. L. et al.
Bridging the age gap in breast cancer: impact of omission
of breast cancer surgery in older women with oestrogen
receptor-positive early breast cancer on quality-of-life
outcomes
J L Morgan 1, A Shrestha1, M W R Reed 2, E Herbert3, M Bradburn3, S J Walters3, C Martin1, K Collins4, S Ward 5, G Holmes 5,
M Burton3, K Lifford6, A Edwards6, A Ring7, T Robinson8, T Chater3, K Pemberton3, A Brennan5, K L Cheung9, A Todd1,
R Audisio10, J Wright2, R Simcock2, A M Thomson11, M Gosney12, M Hatton13, T Green14, D Revill14, J Gath14, K Horgan15,
C Holcombe16, M C Winter13, J Naik17, R Parmeschwar18 and L Wyld 1,*
1Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK
2Brighton and Sussex Medical School, Brighton, UK
3Clinical Trials Research Unit, School for Health and Related Research, University of Sheffield, Sheffield, UK
4Faculty of Health and Wellbeing, Department of Allied Health Professions, Sheffield Hallam University, Sheffield, UK
5Department of Health Economics and Decision Science, School for Health and Related Research, ScHARR, University of Sheffield, Sheffield, UK
6Division of Population Medicine, Cardiff University, Cardiff, UK
7Department of Medical Oncology, Royal Marsden Hospital, London, UK
8Department of Cardiovascular Sciences and National Institute for Health Research Biomedical Research Centre, University of Leicester, Cardiovascular Research
Centre, Glenfield General Hospital, Leicester, UK
9School of Medicine, University of Nottingham, Royal Derby Hospital, Derby, UK
10Department of Surgery, University of Gothenberg, Sahlgrenska Universitetssjukhuset, Gothenberg, Sweden
11Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
12School of Psychology and Clinical Language Sciences, University of Reading, Reading, UK
13Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital, Sheffield, UK
14North Trent Cancer Research Network Consumer Research Panel, Sheffield, UK
15Department of Breast Surgery, Bexley Cancer Centre, St James’s University Hospital, Leeds, UK
16Department of Breast Surgery, Liverpool University Hospitals Foundation Trust, Liverpool, UK
17Department of General Surgery, Pinderfields Hospital, Mid Yorkshire NHS Foundation Trust, Wakefield, UK
18Department of Breast Surgery, University Hospitals of Morecambe Bay, Lancaster, UK
*Correspondence to: Department of Oncology and Metabolism, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK (e-mail:
l.wyld@sheffield.ac.uk)
Abstract
Background: Primary endocrine therapy may be an alternative treatment for less fit women with oestrogen receptor (ER)-positive
breast cancer. This study compared quality-of-life (QoL) outcomes in older women treated with surgery or primary endocrine
therapy.
Methods: This was a multicentre, prospective, observational cohort study of surgery or primary endocrine therapy in women
aged over 70 years with operable breast cancer. QoL was assessed using European Organisation for Research and Treatment of cancer
QoL questionnaires QLQ-C30, -BR23, and -ELD14, and the EuroQol Five Dimensions 5L score at baseline, 6 weeks, and 6, 12, 18, and
24 months. Propensity score matching was used to adjust for baseline variation in health, fitness, and tumour stage.
Results: The study recruited 3416 women (median age 77 (range 69–102) years) from 56 breast units. Of these, 2979 (87.2 per cent) had
ER-positive breast cancer; 2354 women had surgery and 500 received primary endocrine therapy (125 were excluded from analysis
due to inadequate data or non-standard therapy). Median follow-up was 52 months. The primary endocrine therapy group was older
and less fit. Baseline QoL differed between the groups; the mean(s.d.) QLQ-C30 global health status score was 66.2(21.1) in patients
who received primary endocrine therapy versus 77.1(17.8) among those who had surgery plus endocrine therapy. In the unmatched
analysis, changes in QoL between 6 weeks and baseline were noted in several domains, but by 24 months most scores had returned
to baseline levels. In the matched analysis, major surgery (mastectomy or axillary clearance) had a more pronounced adverse impact
than primary endocrine therapy in several domains.
Conclusion: Adverse effects on QoL are seen in the first few months after surgery, but by 24 months these have largely resolved.
Women considering surgery should be informed of these effects.
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Introduction
Although surgery is a key element of treatment for early breast
cancer, it may sometimes be avoided in the frail older patient,
who may instead be managed with primary endocrine therapy.
Use of primary endocrine therapy instead of surgery was first
suggested by Preece and colleagues1 in 1980, and has been
adopted variably across the globe2; some countries treat up to 40
per cent of women aged over 70 years using primary endocrine
therapy, whereas others, such as the USA, use it rarely. The ratio-
nale is that in oestrogen receptor (ER)-positive cancer, disease
control may be achieved for several years with primary endocrine
therapy, with minimal morbidity. Frail older women with a short-
ened life expectancy may die from other causes before the cancer
develops resistance to endocrine therapy, and so any adverse im-
pact of surgery on quality of life (QoL) can be avoided. In particu-
lar, a frail older patient undergoing general anaesthesia may
suffer a long-term reduction in functional capacity, along with
risks of local and systemic complications. Numerous studies
have shown that older patients value QoL at least as highly as
length of life, and wish to maintain their QoL and independence
for as long as possible to avoid being a burden to family and
carers3.
The evidence base for the health threshold at which primary
endocrine therapy becomes appropriate is limited. European
Society of Breast Cancer Specialists and the Society of Geriatric
Oncology guidelines4 recommend surgery for all women who are
fit enough, but do not specify any health or fitness parameters
for this assessment.
There are few published data on the QoL impact of primary
endocrine therapy versus surgery, The Cancer Research
Campaign trial5, one of the early randomized trials comparing
surgery and primary endocrine therapy, included a QoL substudy
that used the General Health Questionnaire score up to 2 years
after diagnosis. The median interval until first assessment was
12 months after treatment had started in both arms, and there-
fore at a time when much of the impact of surgery would have re-
solved. The study found that 9 of 49 patients in the surgery group
and 2 of 49 in the primary endocrine therapy group had scores in-
dicative of psychiatric morbidity; by 2 years, the numbers were 6
of 49 in both arms. Moreover, at the time of the Cancer Research
Campaign trial, there were no validated tools for assessment of
the specific impact of breast cancer and its treatment nor ques-
tionnaires evaluating more general issues, such as ability to func-
tion normally. Subsequently, the European Organisation for the
Research and Treatment of Cancer (EORTC) developed a generic
cancer QoL instrument (QLQ-C30)6, and a breast cancer-specific
instrument (QLQ-BR23)7 with domains specific to breast cancer
treatment effects. Another EORTC instrument has been devel-
oped more recently specifically to record QoL concerns relevant
to elderly patients (QLQ-ELD15)8. No studies have compared QoL
outcomes between surgery and primary endocrine therapy using
these highly specific and validated tools.
A previous study3 of older women who had faced the choice of
primary endocrine therapy versus surgery demonstrated that
disability-free life expectancy, QoL, and independence were key
priorities3, along with fear of surgery, anaesthesia, and hospitali-
zation. Although surgery and anaesthesia have become safer in
recent years, and breast surgery in particular is associated with a
very low mortality rate9, morbidity rates may be substantial10.
A recent study11 from the USA of frail older women with breast
cancer reported that those living in nursing homes had high rates
of mortality from surgery, significant rates of death within 1 year
(implying that the surgery was of negligible benefit), and signifi-
cant rates of functional decline after surgery. In this frailer older
group surgery may therefore be harmful and convey little benefit,
but impair highly valued QoL.
The Age Gap study was designed to determine age and health-
stratified outcomes (including QoL) of surgery or primary
endocrine therapy in older women with early breast cancer. The
aim of the present study was to use a range of validated tools to
provide a comprehensive evaluation of the impact of treatment,
specifically comparing surgery plus endocrine therapy versus pri-
mary endocrine therapy, for early ER-positive breast cancer in
older women, with a focus on factors including disability-free life
expectancy, QoL, and independence.
Methods
Ethics and research governance approvals were obtained (IRAS:
12 LO 1808). All patients gave written informed consent to partici-
pate. The study was sponsored by Doncaster and Bassetlaw
Teaching Hospitals NHS Foundation Trust, and registered as
ISRCTN46099296.
Study design
This was a prospective, longitudinal, multicentre observational
cohort study. Patients could participate at three levels: full partic-
ipation, partial (no requirement to complete QoL assessments) or
by proxy consent (simple third-party data collection for women
with cognitive impairment). Trial reporting complies with
STROBE guidelines12. The data in this paper relate only to women
who consented to full participation.
Patients
Patients were recruited from 56 breast units in England and
Wales (Table S1). Inclusion criteria were: women aged 70 years
age or above at the time of breast cancer diagnosis with primary
operable invasive breast cancer (TNM stages T1–3 and some
T4b N0–2 M0). Women with multifocal and bilateral cancers were
eligible. Exclusion criteria were: inoperable disease, and previous
breast cancer within 5 years.
Baseline health assessment
Women were recruited at the time of breast cancer diagnosis and
before commencement of treatment. Baseline health assessment
was undertaken before treatment started using validated tools to
permit baseline adjustment and reduce allocation bias. This in-
cluded evaluation of co-morbidities (Charlson co-morbidity in-
dex, CCI13); nutrition (Abridged Patient Generated Subjective
Global Assessment, aPG-SGA14–16); physical function (Barthel
Activities of Daily Living, ADL)17; complex physical functioning
(Instrumental Activities of Daily Living, IADL18; cognitive status
(Mini-Mental State Examination, MMSE19); Eastern Cooperative
Oncology Group Performance status, ECOG-PS)20; medication;
and QoL assessment (see below).
Quality-of-life assessment
Four validated instruments were used for QoL assessment
(Table S2). The EORTC QLQ-C306 generic QoL instrument has 28
questions covering seven domains, including physical, emotional,
and role function, and two visual analogue scales (VAS) rating
health status and QoL today. The EORTC-QLQ-BR237, is a breast-
specific QoL module, which has 23 questions covering domains
relevant to breast cancer therapies such as body image, breast
symptoms, arm symptoms, chemotherapy, and endocrine
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therapy symptoms. The EORTC-QLQ-ELD158 is an older person-
specific module, which has 15 questions relating to five domains
including mobility, and maintaining autonomy and purpose.
Finally, the EuroQol Five Dimensions 5L (EQ-5D-5LTM; EuroQoL
Group, Rotterdam, the Netherlands)21 is a generic instrument,
with five domains including mobility, self-care and usual activi-
ties, and a VAS. (It was also used for health economic evaluation,
which is reported separately). Measures of independence were
taken from the usual activities section of the EQ-5DTM and some
of the functional domains of the other questions.
Tumour and treatment data
The following baseline tumour data were collected: cancer
type, grade, nodal status, tumour size (clinical and on imaging),
oestrogen, progesterone, and human epidermal growth factor re-
ceptor 2 status, and Oncotype DX scores (if available). Staging for
metastatic disease was performed if indicated clinically, but oth-
erwise M0 was presumed.
Type of surgery, use of radiotherapy, and use and type of any
systemic therapy were recorded. Baseline assessment of the tu-
mour was undertaken using the Response Evaluation Criteria in
Solid Tumours22 to permit monitoring of the response to primary
endocrine therapy. Type of surgery was classified as major (mas-
tectomy and/or axillary clearance) or minor (wide local excision
and/or sentinel lymph node biopsy) for some evaluations as a
post hoc analysis.
Follow-up
Patients were followed up at 1.5, 6, 12, 18, and 24 months, with
QoL assessment at each of these time points
Statistical analysis
The QLQ-C30, -BR23, and -ELD15 were scored according to the
EORTC Scoring Manual (3rd edition)23 and reference publica-
tions8,24. The EQ-5D-5LTM was used as a QoL measure for this
analysis, with individual questions scored from 1 to 5; higher
scores indicated better responses. An overall score from 0 to 1
was calculated, where higher scores indicated better QoL25.
Missing data were managed according to EORTC recommenda-
tions.
P< 0.050 was was considered statistically significant. Analyses
were done in SPSSVR version 24 (IBM, Armonk, New York, USA), R
version 3.6.3 (R Foundation for Statistical Computing, Vienna,
Austria) and StataVR (StataCorp, College Station, Texas, USA).
Propensity score matching
Propensity score matching was used to identify patients with
similar baseline characteristics in groups of patients undergoing
surgery plus endocrine therapy or primary endocrine therapy, in
an attempt to correct for allocation bias and allow a more direct
comparison between groups.
Propensity scores for treatment allocation were calculated by
means of logistic regression, and then used to match patients in
the two treatment groups. The co-variables included were meas-
ures of functionality (ADL, IADL, MMSE, ECOG-PS), nutritional
status (nutrition (aPG-SGA), co-morbidities (CCI, number of medi-
cations), and age (Table S3).
The ratio and caliper widths of the propensity scores were
chosen based on examination of propensity score overlaps for
several combinations of ratios and calipers. A 1 : 2 ratio for pri-
mary endocrine therapy to surgery plus endocrine therapy, and a
caliper of 0.25 times the propensity scores standard deviation
were used to optimally match quality and numbers. Participants
were also matched exactly with respect to Nottingham
Prognostic Index26 category (good, below 3.5; moderate, 3.5–5.4;
poor, over 5.4) to avoid fit participants with aggressive cancer
being matched with frail participants who had a smaller cancer.
The impact of major or minor surgery versus primary endo-
crine therapy on domains of interest from each questionnaire
was compared by fitting longitudinal mixed-effect models to the
propensity score-matched data with treatment (minor surgery,
major surgery or primary endocrine therapy), time, treatment–
time interaction, and the baseline score as co-variables. The
models were then used to estimate marginal effects of minor or
major surgery versus primary endocrine therapy at each time
point.
Results
The study recruited 3416 women between February 2013 and
June 2018, with a median age of 77 (range 69–102) years (Fig. 1).
Of these, only 3315 were fully eligible for analysis. The majority
(2854, 86.1 per cent) had ER-positive breast cancer and were
therefore potential candidates for the analysis of surgery plus en-
docrine therapy versus primary endocrine therapy. The following
results relate only to patients with ER-positive breast cancer.
Survival and recurrence outcomes have been published sepa-
rately10. Broadly, in the unmatched unadjusted analyses, overall
survival (OS) and breast cancer-specific survival (BCSS) were
poorer in the primary endocrine therapy group than among
patients who had surgery and endocrine therapy (OS: HR 0.27, 95
per cent c.i. 0.23 to 0.33, P< 0.001; BCSS: HR 0.89, 0.52 to 1.53,
P¼ 0.68). On matching, these differences decreased (OS: adjusted
HR 0.72, 0.53 to 0.98; P¼ 0.037) or disappeared (BCSS: HR 0.74,
0.40 to 1.37; P¼ 0.340), suggesting that, in a cohort of older frailer
women, there was no survival advantage to surgery at 52 months’
follow-up.
Of the 2854 patients with ER-positive breast cancer, 2354
underwent surgery (60.1 per cent breast conservation, 39.9 per
cent mastectomy10) and 500 commenced primary endocrine ther-
apy (82.8 per cent with letrozole, 6.2 per cent with anastrazole,
4.4 per cent with tamoxifen, 1.4 per cent with exemestane, 5.2
per cent type unknown). Of the 2354 surgical patients, 255 (10.8
per cent) also had chemotherapy within 12 months of diagnosis,
and 1363 (57.9 per cent) underwent radiotherapy within 12
months of diagnosis. The impact of adjuvant chemotherapy and
radiotherapy on QoL has been analysed and will be published
separately. Patient, tumour, and treatment characteristics are
summarized in Tables 1 and 2. Patients undergoing surgery were
generally younger, fitter, and had better functionality than those
undergoing primary endocrine therapy. Women in the surgery
group had additional therapies including endocrine therapy, ra-
diotherapy, chemotherapy, and trastuzumab variously according
to clinical indication at various time points (Fig. S1).
Most surgery had taken place by the 6-week time point, al-
though a small number of primary operations were undertaken
between 6 weeks and 6 months (Fig. S1). For the purpose of this
analysis, therefore, the impact of surgery is presumed to be rep-
resented by the change between baseline and 6 weeks.
Matching was undertaken to reduce baseline variation in
health status, resulting in a matched population of 238 patients
who had primary endocrine therapy (47.6 per cent), 184 of whom
were matched with two surgical patients and 54 with only one.
Matching quality was good (Table S3).
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Data completeness
QoL data were available for 1644 of 2354 surgical patients (69.8
per cent) and 254 of 500 (50.8 per cent) in the primary endocrine
therapy group. Not all women completed 2-year follow-up be-
cause of discontinuation (deaths, withdrawals). Finally, some
forms were not completed or completed inadequately, meaning
that full data were not available for all patients. Owing to this at-
trition in numbers completing forms, especially in the primary
endocrine therapy group, statistical interpretation was not possi-
ble for some domains; however, clear and clinically relevant var-
iations and trends were seen in the data, as presented below.
Because of the variation in baseline QoL in all domains (owing
to the different characteristics of women in each group),
unmatched data are presented so that temporal trends resulting
from treatment can be seen in all-comers (the matched group,
plus very fit surgical patients and very unfit patients who re-
ceived primary endocrine therapy for whom matching was not
possible). Statistical comparison of these raw unmatched data
was not possible owing to the wide variation in baseline QoL;
therefore, statistical analysis was performed only on the matched
data set in which baseline variation was minimized, making di-
rect comparison of surgery plus endocrine therapy versus primary
endocrine therapy more appropriate.
Generic cancer quality-of-life outcomes: EORTC-
QLQ-C30
The proportion of patients with full participation who completed
the QLQ-C30 global health status score at baseline was 1902 of
2065 (92.1 per cent), of whom 1644 of 1772 (92.8 per cent) had sur-
gery plus endocrine therapy and 258 of 293 (88.1 per cent) pri-
mary endocrine therapy. At 24 months, these numbers had
reduced to 984 of 2065 (47.7 per cent) in total, of whom 902 of
1772 (50.9 per cent) had surgery plus endocrine therapy and 82 of
293 (28.0 per cent) primary endocrine therapy. Full data
(mean(s.d.) scores at all time points with numbers of comple-
tions) are shown in Table S4. Considering the differences in age,
and health and fitness characteristics beween women treated
with primary endocrine therapy and those who had surgery plus
endocrine therapy, patients who received primary endocrine
therapy had worse baseline scores across all domains of the QLQ-
C30 (mean(s.d.) global health status score 66.2(21.1) and
77.1(17.8) respectively) (Table S4). In the surgery plus endocrine
therapy group, a steep drop in mean scores between baseline and
6 weeks was apparent in the role functioning and social function-
ing domains, and an increase in fatigue and pain scores, com-
pared with values in the primary endocrine therapy group
(Fig. 2a–d).
Global health status scores (questions 29 and 30 of the instru-
ment), which are calculated from two VAS (ranging from 1 (very
poor) to 7 (excellent)) asking the questions ‘how would you rate
your health today?’ and ‘how would you rate your quality of life
today?’ were compared between the unmatched and matched
groups. In the unmatched analysis, the observed baseline in
global health status in the two groups persisted throughout the
2-year follow-up, although temporal trends owing to treatments
were apparent. On matching, the two curves largely overlapped
once baseline variation had been accounted for (Fig. S2).
Analysis according to whether the surgery was major or minor
highlighted the impact of major surgery compared with primary
endocrine therapy on several key domains of the QLQ-C30 instru-
ment. The effects of minor or major surgery compared with pri-
mary endocrine therapy were small and broadly similar for all
four domains across time points (Fig. 3). The biggest differences
were noted for role functioning; major surgery had a marked neg-
ative effect at 6 weeks compared with primary endocrine therapy
(mean difference –9.59, 95 per cent c.i. –16.96 to –2.21). This nega-
tive effect decreased with time. Fatigue was also more negatively
affected by major surgery; levels of fatigue were higher after sur-
gery than those associated with primary endocrine therapy, and
took longer to recover. Minor surgery had less impact compared
with primary endocrine therapy for both fatigue and role func-
tioning. Levels of pain were higher in the surgery plus endocrine
therapy group after both major and minor surgery compared
with primary endocrine therapy.
Breast cancer-specific quality-of-life outcomes
(EORTC-QLQ-BR23)
Mean(s.d.) scores for each domain of the QLQ-BR23 at each time
point are shown in Table S5. For most domains, there were no
great differences in scores between the groups at 6 weeks, but
there were several notable domains where the impact of surgery
was apparent (Fig. 2e,f). Breast symptom scores in the surgery








Eligible for comparison of surgery







254 of 500 (50.8%)
quality-of-life data
available










Fig. 1 Study flow diagram






/bjs/advance-article/doi/10.1093/bjs/znaa125/6184678 by guest on 26 M
arch 2021
whereas a minimal change from 10.1(15.7) to 10.8(15.7) was docu-
mented in the primary endocrine therapy group. The score for
the surgery plus endocrine therapy group had returned to normal
by 24 months.
Patients in the surgery group also had a marked increase in
arm symptom score at 6 weeks, whereas those who received pri-
mary endocrine therapy did not (increase in mean score from
8.4(14.1) to 16.6(18.3) and from 12.5(18.1) to 14.0(18.9) respec-
tively). Scores in the surgery plus endocrine therapy group had
not returned to baseline levels even by 24 months. For both
groups, the degree of reduction in body image score was similar
when all types of surgery were analysed together. Scores were
similar for other domains.
The sexual enjoyment comparison was not valid because of
the extremely small number of women who completed these
questions, especially in the primary endocrine therapy group.
In the matched cohort, examination of the QLQ-BR23 domains
according to minor or major surgery reinforced the impact of
surgery on arm function. In longitudinal models fitted to the
matched cohort, it was found that women who had major sur-
gery had significantly worse arm symptoms at the 6-week time
point than those who had primary endocrine therapy (mean dif-
ference 8.85, 95 per cent c.i. 3.63 to 14.07). Women who under-
went minor surgery also had more arm symptoms than those
who had primary endocrine therapy, but with a smaller differ-
ence (Fig. 4).
Older age-specific quality-of-life outcomes
(EORTC-QLQ-ELD15)
In the unmatched data, patients treated with primary endocrine
therapy had worse baseline scores than those who had surgery
plus endocrine therapy for mobility problems (mean(s.d.) base-
line scores 39.3(33.2) and 15.5(22.5) respectively) (Table S6).
Similarly, joint stiffness scores were worse in the primary endo-
crine therapy group at baseline (43.3(35.7) versus 27.1( 27.9)).
Other scores were similar at baseline.







Age (years) n ¼ 500 n ¼ 2354 n ¼ 2854
Mean(s.d.) 83.5(6.5) 76.4(5.1) 77.6 (6.0)
Median (i.q.r.; range) 84 (79–88; 70–102) 76 (72–80; 69–94) 77 (73–82; 69–102)
aPG-SGA score n ¼ 322 n ¼ 2021 n ¼ 2343
Mean(s.d.) 2.3(3.1) 1.2(2.2) 1.4(2.4)
Median (i.q.r.; range) 1 (0–3; 0–18) 0 (0–2; 0–17) 0 (0–2; 0–18)
Modified CCI score n ¼ 459 n ¼ 2273 n ¼ 2732
Mean(s.d.) 5.8(2.0) 4.3(1.4) 4.5(1.6)
Median (i.q.r.; range) 6 (4–7; 3–17) 4 (3–5; 3–13) 4 (3–5; 3–17)
Barthel ADL index score n ¼ 399 n ¼ 2135 n ¼ 2534
Mean(s.d.) 88.8(16.6) 97.7(6.2) 96.3(9.3)
Median (i.q.r.; range) 95 (85–100; 5–100) 100 (100–100; 10–100) 100.0 (95–100; 5–100)
IADL index score n ¼ 382 n ¼ 2104 n ¼ 2486
Mean(s.d.) 6.1(2.1) 7.6(0.9) 7.4(1.3)
Median (i.q.r.; range) 7 (5–8; 0–8) 8 (8–8; 0–8) 8 (7–8; 0–8)
MMSE score n ¼ 273 n ¼ 1631 n ¼ 1904
Mean(s.d.) 26.7(3.7) 28.3(2.5) 28.1(2.8)
Median (i.q.r.; range) 28 (26–29; 10–30) 29 (28–30; 10–30) 29 (27–30; 10–30)
ECOG-PS score n ¼ 453 n ¼ 2240 n ¼ 2693
Fully active 137 (30.2) 1659 (74.1) 1796 (66.7)
Restricted in physically strenuous activity 167 (36.9) 481 (21.5) 648 (24.1)
Ambulatory and capable of all self-care 67 (14.8) 68 (3.0) 135 (5.0)
Capable of only limited self-care 75 (16.6) 31 (1.4) 106 (3.9)
Completely disabled 7 (1.5) 1 (0.0) 8 (0.3)
No. of current medications n ¼ 450 n ¼ 2050 n ¼ 2500
Mean(s.d.) 5.0(3.0) 4.1(2.6) 4.2(2.7)
Median (i.q.r.; range) 5 (3–7; 0–18) 4 (2–5; 0–18) 4 (2–6; 0–18)
aPG-SGA risk category n ¼ 376 n ¼ 2109 n ¼ 2485
Low 291 (77.4) 1848 (87.6) 2139 (86.1)
Moderate 62 (16.5) 227 (10.8) 289 (11.6)
High 23 (6.1) 34 (1.6) 57 (2.3)
ADL risk category n ¼ 408 n ¼ 2172 n ¼ 2580
No dependency 191 (46.8) 1684 (77.5) 1875 (72.7)
Mild dependency 53 (13.0) 258 (11.9) 311 (12.1)
Moderate/severe dependency 164 (40.2) 230 (10.6) 394 (15.3)
IADL risk category n ¼ 403 n ¼ 2158 n ¼ 2561
No dependency 158 (39.2) 1759 (81.5) 1917 (74.9)
Mild dependency 64 (15.9) 193 (8.9) 257 (10.0)
Moderate/severe dependency 181 (44.9) 206 (9.5) 387 (15.1)
MMSE risk category n ¼ 500 n ¼ 2354 n ¼ 2854
Normal function 362 (72.4) 2095 (89.0) 2457 (86.1)
Mild impairment 75 (15.0) 206 (8.8) 281 (9.8)
Moderate impairment 20 (4.0) 29 (1.2) 49 (1.7)
Severe impairment 43 (8.6) 24 (1.0) 67 (2.3)
Values in parentheses are percentages unless indicated otherwise. aPG-SGA, Abridged Patient Generated Subjective Global Assessment; CCI, Charlson Co-morbidity
Index; ADL, Activities of Daily Living; IADL, Instrumental ADL; MMSE, Mini-Mental State Examination; ECOG-PS, Eastern Cooperative Oncology Group Performance
Status.
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No. of clinically involved nodes detectable n ¼ 483 n ¼ 2309 n ¼ 2792
Mean(s.d.) 0.2(0.6) 0.2(0.8) 0.2(0.7)
Median (i.q.r.; range) 0 (0–0; 0–4) 0 (0–0; 0–20) 0 (0–0; 0–20)
Tumour size (mm) n ¼ 487 n ¼ 2318 n ¼ 2805
Mean(s.d.) 23.9(12.0) 19.2(12.3) 20.0(12.4)
Median (i.q.r.; range) 21 (16–30; 0–70) 17 (11–24; 0–150) 18 (12–25; 0–150)
Nottingham Prognostic Index score n ¼ 456 n ¼ 2172 n ¼ 2628
Mean(s.d.) 3.5(0.8) 3.5 (0.8) 3.5 (0.8)
Median (i.q.r.; range) 3.4 (3.2–3.9; 2.1–7.0) 3.3(3.2–4.0; 2.0–6.7) 3.4 (3.2–4.0; 2.0–7.0)
Side of primary tumour n ¼ 500 n ¼ 2354 n ¼ 2854
Right 223 (44.6) 1084 (46.0) 1307 (45.8)
Left 277 (55.4) 1270 (54.0) 1547 (54.2)
HER2 amplification n ¼ 359 n ¼ 1911 n ¼ 2270
Negative 311 (86.6) 1641 (85.9) 1952 (86.0)
Inconclusive 14 (3.9) 70 (3.7) 84 (3.7)
Positive 34 (9.5) 200 (10.5) 234 (10.3)
Provisional histological grade n ¼ 484 n ¼ 2243 n ¼ 2727
1 98 (20.2) 399 (17.8) 497 (18.2)
2 329 (68.0) 1475 (65.8) 1804 (66.2)
3 57 (11.8) 369 (16.5) 426 (15.6)
Values in parentheses are percentages unless indicated otherwise. HER2, human epidermal growth factor receptor 2.
100
a   C30: role functioning b   C30: social functioning c   C30: fatigue d   C30: pain
e   BR23: arm symptoms
e   EQ-5D-5LTM: usual activities f   EQ-5D-5LTM: pain/discomfort f   EQ-5D-5LTM: Anxiety/depression















































































































































































































































































































































































































































Fig. 2 Unmatched mean quality-of-life scores
QLQ-C30 a role functioning, b social functioning, c fatigue, and d pain; QLQ-BR23 e arm symptoms and f breast symptoms; QLQ-ELD15 g family support and
h burden of illness; EuroQol Five Dimensions 5L (EQ-5D-5LTM) i usual activities, j pain/discomfort, and k anxiety/depression. Shaded areas represent 95 per cent
confidence intervals.
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At the 6-week time point, the most noticeable change in the
surgery plus endocrine therapy group was in scores for burden of
illness, which increased from a mean of 20.3(23.5) to 30.4( 24.7),
whereas the score increased from 21.1(23.8) to 25.2(27.5) in the
primary endocrine therapy group (Fig. 2h). Scores for burden of
illness had returned to baseline levels in the surgery group by
18 months.
Domains of interest in the QLQ-ELD15 were analysed using
longitudinal modelling in the matched cohort to compare major
or minor surgery with primary endocrine therapy. Patients who
had major surgery had a greater burden of illness at the 6-week
time point than those treated with primary endocrine therapy
(mean difference 7.57, 95 per cent c.i. 0.58 to 14.56). In contrast,
minor surgery appeared to have a less marked impact (mean dif-
ference 5.17, –1.99 to 12.32) (Fig. 5a).
EQ-5D-5L
TM
and visual analogue scale outcomes
Summaries of the overall EQ-5D-5LTM score calculated from all
questions and the VAS score showed a substantial difference be-
tween baseline scores in the unmatched population owing to
imbalances in age and health status (Table S7).
Analysis by question showed the impact of surgery on several
aspects, notably ability to perform usual activities, pain and dis-
comfort, and anxiety and depression (Fig. 2i–k). All of these scores
worsened between baseline and 6 weeks when surgery usually
took place. It is noteworthy that for none of these domains did
the scores return to baseline levels after this treatment had led to
deterioration. In the primary endocrine therapy group, the pat-
tern was more of a slow decline over the entire 2-year interval.
In the matched analysis by domain, many of the differences
between surgery (major and minor) disappeared (Fig. 5b–d).
Discussion
This study included data from a large, multicentre cohort study
of women with operable breast cancer treated between 2013 and
2018, 82.5 per cent of whom had surgery as primary treatment.
Surgery plus endocrine therapy was shown to have a discernible
and clinically valid impact on a range of QoL domains. Women
undergoing major surgery had more noticeable changes in pain,
role functioning, social functioning, and arm symptoms than
those who received primary endocrine therapy which is in keep-
ing with clinical observations. It is noteworthy that, although the
majority of scores returned to baseline levels by 24 months, this
was not always the case and for some there appeared to be per-
manent impairment. Again, this accords with clinical observa-
tions, particularly in respect of axillary lymph node clearance,
after which long-term shoulder stiffness, lymphoedema and pain
are relatively common chronic side-effects.
In the primary endocrine therapy group, the pattern of
change was largely a slow decline across all domains over the
2-year interval. There was an increase in mobility problems in
both groups, which progressed slowly over time, and probably
relates to the fact that the majority of the women in both
groups were taking an aromatase inhibitor throughout this pe-
riod, which is known to cause joint pain. This was also seen in
the QLQ-ELD15 domain for joint stiffness, where there was a
sharp rise in symptoms between 6 weeks and 6 months in both
groups; this was in line with most women having started
6 weeks
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Fig. 3 Longitudinal modelling of effect of minor or major surgery versus primary endocrine therapy on QLQ-C30 scores in matched cohort
a Global health status/quality of life (QoL), c fatigue, and d pain. Effect sizes are shown with 95 per cent confidence intervals.
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aromatase inhibitor therapy between baseline and 8 weeks af-
ter diagnosis.
The impact of cancer treatment was well reflected in the
EQ-5D-5LTM score for usual activities. There was a marked
decline between baseline and 6 weeks in the surgery plus endo-
crine therapy group, but this never recovered and plateaued at
this lower level after treatment. In the primary endocrine
therapy group, there was just a slow steady decline across the
study interval.
For some women, surgery plus endocrine therapy causes
both acute and long-term pain, as seen in both the QLQ-C30
and the EQ-5D-5LTM pain domains. Levels of pain increased
sharply between baseline and 6 weeks, but never really recov-
ered.
6 weeks
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a   BR23: body image b   BR23: breast symptoms
c   BR23: arm symptoms
Fig. 4 Longitudinal modelling of effect of minor or major surgery versus primary endocrine therapy on QLQ-BR23 scores in matched cohort
a Body image, c breast symptoms, and c arm symptoms. Effect sizes are shown with 95 per cent confidence intervals.
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The survival data for this study have been published else-
where10, and highlight that, for some older frailer patients with
breast cancer who have limited life expectancy, standard therapy
with surgery plus endocrine therapy may offer limited survival
benefit but with a potential reduction in QoL in the short term,
with some patients not recovering fully from these effects by
2 years. Women in this borderline group, which appears to in-
clude those in moderate or poor health aged over age 85 years, or
women older than 90 years (equating to a predicted life expec-
tancy of less than 5 years), should be offered an informed choice
of breast cancer treatment and be supported in making the deci-
sion based on their own preferences. The Age Gap Decision Tool
(https://agegap.shef.ac.uk/) has been developed based on UK reg-
istry data; it has been fully validated27 and tested with older
women for usability and acceptability28–30 to aid in this type of
shared decision-making. Recruiting older patients is challenging
and many trials fail to recruit well from this age group. The Age
Gap study was no exception, and recruited greater numbers of
women in their early 70s and fewer in their 90s. Similarly, rates
of deaths and withdrawals were higher in the older age groups. In
addition, women were able to opt out of QoL form completion to
reduce the burden of the trial for frailer patients, and women
with severe cognitive impairment were also not expected to com-
plete the forms. Consequently, the study population did not fully
represent the UK population of older women and failed to cap-
ture QoL outcomes for the oldest and frailest. However, it is based
on real-world UK data and represents a large older breast cancer
population.
There was attrition in the data collection for QoL forms
and different numbers of patients completed the questions at
baseline compared with other time points, which could be a
confounding factor. The population was heterogeneous with
6 weeks
a   ELD15: burden of ilness
c   EQ-5D-5LTM: pain/discomfort d   EQ-5D-5LTM: anxiety depression
b   EQ-5D-5LTM: usual activities
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Minor surgery versus primary endocrine therapy
Major surgery versus primary endocrine therapy
Fig. 5 Longitudinal modelling of effect of minor or major surgery versus primary endocrine therapy on QLQ-ELD15 and EuroQol Five Dimensions
scores in matched cohort
a ELD15: burden of illness; EuroQol Five Dimensions 5L (EQ-5D-5LTM) b usual activities, c pain/discomfort, and d anxiety/depression. Effect sizes are shown with
95 per cent confidence intervals.
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some older women in excellent health, but others very frail with
co-morbidity; consequently, baseline scores in the majority of
QoL domains varied widely, with wide standard deviations
around mean values because of the heterogeneous population,
reduced numbers in the primary endocrine therapy arm of the
study and attrition, and also significant differences between
treatment groups. This was addressed in part by matching, but
this process reduced the number of patients for analysis and
therefore the power of the study. The matching process provided
information on a group for whom UK surgeons seem to have col-
lective equipoise about optimal treatment selection, but also ex-
cluded very fit surgical patients and the least fit patients treated
with primary endocrine therapy, for whom these comparisons
may not be valid. The ideal way of studying this issue would be to
undertake an RCT. Such a trial (ESTEEM) was attempted, but was
unsuccessful owing to poor recruitment as a consequence of lack
of patient and clinician equipoise31.
A further complexity was the variation in treatments in the
surgery plus endocrine therapy group. These patients had sur-
gery varying between mastectomy and reconstruction plus axil-
lary lymph node clearance at one extreme and wide local
excision only at the other. Some women also had chemotherapy
and radiotherapy. ‘Surgery plus endocrine therapy’ should be
more appropriately referred to as ‘standard therapy’. An attempt
was made to address this by subcategorization of surgery as ma-
jor or minor, with a focus on the 6-week time point, at which
stage the majority of women had only undergone surgery and
not adjuvant radiotherapy or chemotherapy. Detailed analysis of
the impact of chemotherapy and radiotherapy will be the subject
of separate analyses. The temporal trends showing the impact of
surgery were clinically as expected and therefore it was felt that
the conclusions are valid.
From this large study of the impact of treatment on QoL in
older women with operable breast cancer, it is clear that breast
cancer treatment has a negative impact on QoL, which is most
notable after surgery. For most patients, QoL gradually returns to
baseline level, but some residual impairment remains at 24
months after diagnosis. It is known that surgery is more effective
than primary endocrine therapy in curing and controlling breast
cancer in most women, with a significant benefit in terms of local
control and survival. This must be traded against a reduction in
short-term QoL, and women must be made aware that they may
suffer some longer-term impairments. There is evidence that QoL
and preservation of independence are of relatively higher value
for older women than for younger women3. Frailer women with
co-morbidities and a reduced life expectancy may gain little sur-
vival benefit from surgery, and potentially suffer long-term dete-
rioration in QoL and function as a result of the operation, which
should be taken into account when supporting shared decision-
making.
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